About HANSOH PHARMA Company

Our company is one of China's leading pharmaceutical companies driven by R&D and innovation. It is committed to meeting patients' unmet clinical needs and improving human health and welfare through continuous innovation. The company has established leading positions in some of the largest and fastest growing treatment fields with significant unmet clinical needs in China, including anti-tumor, anti-infective, central nervous system diseases, and metabolic diseases. Focusing on innovation is the core driving force of the company's development. The Group continues to increase its investment in R&D year by year, established a complete R&D platform and mastered some proprietary technologies, and developed and stored a series of innovative drugs at different stages of R&D. The Group has approved five Class 1 innovative drugs and one imported innovative drug to be marketed in China, and all have been entered into the national health insurance catalogue published by the National Health Insurance Administration. During the reporting period, 11 products were approved for listing in the group, including 1 imported innovative drug; 19 new clinical approvals were obtained, all related to innovative drugs; 6 marketing applications were submitted, including 1 innovative drug (including additional indications): the class 1 innovative drug permoxatide (former name: cultured sihematide) was added to treat anemia in patients with non-dialysis chronic kidney disease not treated with erythropoietin. The Group has successfully transformed into an innovative biopharmaceutical company focused on developing and selling innovative drugs, and will continue to enhance its discovery, development and commercial capabilities to better meet the unmet medical needs of patients in China and around the world. The Group is also committed to expanding its product line and product portfolio of innovative therapeutics through collaboration with external partners, utilizing cutting-edge internal and external technologies. As innovative drugs continue to be approved for marketing, the Group is focusing on improving specialized marketing capabilities and promoting medical professionals' understanding and understanding of independently innovative drugs. During the reporting period, sales revenue of innovative drugs was about RMB 5.06 billion, an increase of about 19.1% over the previous year, accounting for the Group's total revenue from 42.3% in the same period last year to 53.4%. The Company attaches great importance to the management and improvement of environmental, social and governance. During the reporting period, the Group continued to maintain the MSCI (Ming Sheng) ESG A rating, and received 63 points in the S&P Global (S&P Global) Corporate Sustainability Assessment (CSA), exceeding 95% of the world's peer companies. It was also selected in the “2023 Sustainable Development Yearbook”, making it the only pharmaceutical company in mainland China selected.